Advanced bloodwork / ApoB
Advanced bloodwork, anchored by apolipoprotein B (ApoB) testing, expands routine blood panels to count atherogenic lipoprotein particles directly rather than estimating cholesterol mass, a method endorsed by ESC/EAS guidelines as equal to or more predictive of cardiovascular risk than standard LDL-cholesterol. It is the most widely linked diagnostic in the Atlas, used as a baseline test across precision health, executive health, and functional medicine providers. Evidence tier: well-evidenced.
What it is
Advanced bloodwork in the longevity context refers to an expanded blood panel that goes well beyond a standard annual physical, typically adding apolipoprotein B (ApoB), inflammatory markers such as high-sensitivity C-reactive protein, advanced lipid fractionation, fasting insulin, and a broader hormonal and metabolic set. ApoB is the structural protein present on every atherogenic lipoprotein particle (LDL, VLDL, and their remnants), so an ApoB measurement counts the actual number of particles capable of depositing cholesterol in arterial walls, rather than estimating cholesterol mass carried by those particles as standard LDL-cholesterol does. Major cardiology and lipidology bodies, including the European Society of Cardiology and the European Atherosclerosis Society, recognize ApoB as equal to or more predictive of cardiovascular risk than LDL-cholesterol, particularly in patients with diabetes, obesity, or high triglycerides where LDL-cholesterol estimates are least reliable. Within the longevity economy, advanced bloodwork functions as the baseline diagnostic layer beneath nearly every other intervention: it is the most commonly offered single test across the Atlas, appearing as a standard inclusion in precision health platforms, executive health programs, and functional medicine practices alike, which is consistent with its status as the most widely linked modality in this directory.
Who it is for
Advanced bloodwork with ApoB is most clinically relevant for adults assessing cardiovascular risk, particularly those with a family history of early heart disease, metabolic syndrome, diabetes, or elevated triglycerides, conditions where standard LDL-cholesterol can understate true risk. In the longevity market, it also serves as the default entry diagnostic for healthy adults seeking a quantified baseline before pursuing further testing or intervention.
What to expect
Advanced bloodwork is typically delivered as a single fasting blood draw, performed by a phlebotomist at a clinic, lab partner site, or via at-home mobile draw, with results returned within days through a clinician consultation or a digital dashboard. Panels generally run several times the size of a standard physical's bloodwork, commonly including ApoB, advanced lipid markers, hs-CRP, fasting insulin and glucose, and expanded thyroid and hormone markers, depending on the provider. Across the Atlas, this appears both as a standalone test (Function Health, InsideTracker) and as the first stage of a broader diagnostic workup (Fountain Life, Biograph, Human Longevity Inc/Health Nucleus), with retesting intervals of roughly six to twelve months common among providers with a longevity orientation.
History and background
ApoB measurement has existed in clinical lipidology for decades, but its prominence in mainstream cardiology guidance increased substantially over the 2010s and 2020s as large cohort and Mendelian randomization studies clarified that particle number, not cholesterol mass, drives atherosclerosis. The 2019 ESC/EAS dyslipidaemia guidelines and subsequent consensus statements explicitly recommended ApoB as an alternative or adjunct risk marker, particularly for patients with discordant LDL and triglyceride results. The longevity industry's adoption of expanded bloodwork as a consumer-facing product is more recent, emerging through direct-to-consumer lab testing platforms in the late 2010s and accelerating as precision health and executive health providers built their commercial offerings around frequent, expanded panels as a baseline service.
Worth knowing
ApoB testing is inexpensive relative to its predictive value, often costing little more than a standard lipid panel, yet it remains absent from many routine primary care physicals despite guideline support, a gap that longevity-oriented providers frequently cite as a reason for their existence. Clinical studies have repeatedly shown that a meaningful minority of patients with normal LDL-cholesterol have elevated ApoB or LDL particle count, meaning standard testing alone can miss real cardiovascular risk. Within the Atlas, advanced bloodwork is the single most-linked modality, appearing across fifteen distinct entities spanning diagnostics-only companies, hybrid clinics, and full longevity centers, reflecting its role as the industry's common diagnostic denominator.
Offered across the Atlas 15
Related modalities